Sucampo Pharmaceuticals Inc

Sucampo Pharmaceuticals — Q1 2014 Earnings Presentation

20 slides from Sucampo Pharmaceuticals's earnings presentation, May 7, 2014

  1. Slide 1: First Quarter 2014 Results

    First Quarter 2014 Results May 7, 2014 e @ SUCAMPO The Science of Innovation

  2. Slide 2: Forward-Looking Statements

    J Statements Silvia Taylor Senior Vice President, Investor Relations d Corp age e ? SUCAMPO 2 The Science of Innovation

  3. Slide 3: Agenda

    Agenda Introducti dE d-Looki Statements Silvia Taylor Highlights of the Quarter Peter Greenleaf (MTT EAe) eee & RESCULA® rf pdate mmercial U, Stanley G. Miele Pipeline and R&D Update Taryn Losch-Beridon Financial Performance Cary J. Claiborne Closing Remarks Peter Greenleaf $ sucaMPo 3 ‘The Science

  4. Slide 4: Forward-Looking Statements

    Forward-Looking Statements= product potential, future others, andlor regulatory actions. new information, 2014. $ sucaMPo 4 ‘The Science of Innovation

  5. Slide 5: Peter Greenleaf

    Peter Greenleaf Chief Executive Officer e @ SUCAMPO 5 The Science of Innovation

  6. Slide 6: Areas of Emphasis

    60 Day Areas of Emphasis ¢ Great PEOPLE ° Great SCIENCE ¢ Strong FUNDAMENTALS $ sucaMpo ‘The Science of Innovation

  7. Slide 7: Q1 2014 Overview & Highlights

    Q1 2014 Overview & Highlig Comprehensive Review of Our Strategy capital struct Operating structure, prostone technology platform, pipeline, partnerships, ure Plan to be shared in Q3 Strong Financial Performance « Reporting 31% YoY growth in revenues + Inthe U.S.: solid performance of AMITIZA In Japa

  8. Slide 8: Stanley G. Miele

    Stanley G. Miele President, Sucampo Pharma Americas, LLC and SVP, Sales and Marketing e @ SUCAMPO 8 The Science of Innovation

  9. Slide 9: Continued AMITIZA YOY Growth

    Continued AMITIZA YOY Growth + Net sales growth ‘owth of Rx growth of 3% for Qt" Market Growth Accelerating Strong Partner Class up 6% for Q1 2014 vs. Q1 2013 increasing patient- focused efforts Over 8M TRx’s in = 8 years?; heritage is driver of increased sal : i com ition; 91% Commercial Part D See

  10. Slide 10: AMITIZA Global Snapshot

    AMITIZA Global Snapshot- Japan va tt t be above our urand Abbot expectation « AMITIZAsales in Japan grew to $6.1M (+177%) « Abbott applying more than half of detailing efforts in Japan to AMITIZA * 2 week limitation removed ¢ Available market is over 21M patients, making Japan a a and growing driver

  11. Slide 11: Taryn Losch-Beridon

    Taryn Losch-Beridon Vice President, Clinical Development e ? SUCAMPO "1 The Science of Innovation

  12. Slide 12: Clinical Focus

    CLINICAL FOCUS LEAD COMPOUNDS PHASE 2 PHASE 3 COMPLETED MPROJECTED START BONGOING *Co-developing with R-Tech Ueno, Ltd SUCAMPO 12 ‘The Science of Innovation

  13. Slide 13: Q1 2014 Performance

    1014 Performance 4 Cary J. Claiborne Chief Financial Officer e ? SUCAMPO 13 The Science of Innovation

  14. Slide 14: Strong Financial Performance

    Strong Financial Performance it gor $0.02 $(0.08) $(3.1) Q1-13 Qi Q1-13 Q1-14 Net Income/(Loss) EPS $ sucampo 14 ‘The Science of Innovation

  15. Slide 15: Q1 AMITIZA U.S. Net Sales

    Qi AMITIZA U.S. Net Sales* ($ND= 75.0 $64.9 $ Q1-13 Q1-14 $ sucampo 15 “As reported by Takeda for royalty caleulation purposes ‘The Science of innovation

  16. Slide 16: Total Revenues and Product Royalty Revenues

    $22.2 Q1-13, Q1-14 Q1-13 Q1-14 Total Revenues* Product Royalty Revenues $sucampo = *® *Co-promotion, contract and collaboration revenue also are components of revenue. ‘The Science of innovation

  17. Slide 17: Product Sales and R&D Revenues

    Q1-13 Q1-14 Q1-13 Q1-14 Product Sales R&D Revenues Revenues $ sucampo 7 ‘The Science of Innovation

  18. Slide 18: Results of Operations

    fs-of Operations COGS: Increased volume of AMITIZA sales in an F's Dama) cas \clusion of clinical trial of our Rpeoret Ta eae tion, lower costs of our LSS trials and the 2013-t terminated collaboration with Numab AG, partially offset by increased spending with the first patients enrollment for the P

  19. Slide 19: Financial Guidance

    Financial Guidance Eull Year 2014 GAAP Net Income $3M -$5M GAAP EPS $0.06 - $0.11 $ sucaMPo ‘9 The Science of innovation

  20. Slide 20: Peter Greenleaf

    Peter Greenleaf Chief Executive Officer e @ SUCAMPO 20 The Science of Innovation

Sucampo Pharmaceuticals — Q1 2014 Earnings Presentation on 6ix